Ductal carcinoma in situ (DCIS) — the most common noninvasive breast neoplasm in the United States, accounting for approximately 20–25% of all breast cancer diagnoses (estimated 55,000–60,000 new cases annually) and representing the preinvasive precursor lesion that has transformed from a rare pathologic curiosity at the time of its initial description to the dominant diagnosis at the center of contemporary breast oncology's most contested clinical decisions — defined histologically as a clonal proliferation of malignant epithelial cells confined within the basement membrane of mammary ducts without invasion into the surrounding stroma (the basement membrane integrity criterion that is both the defining feature of "in situ" status and the morphologic substrate of DCIS's favorable prognosis relative to invasive breast cancer), detected overwhelmingly in the mammographically screened population as calcifications on digital mammography or digital breast tomosynthesis rather than as a palpable mass (mammography-detected microcalcifications account for 80–90% of DCIS presentations, with only 10–20% presenting as a palpable density, nipple discharge, or Paget's disease of the nipple), graded by nuclear grade as low-grade DCIS (small monomorphic nuclei with minimal pleomorphism, low mitotic rate, frequently central necrosis-free cribriform or micropapillary architecture), intermediate-grade DCIS, or high-grade DCIS (large pleomorphic nuclei with prominent nucleoli, brisk mitotic rate, central comedonecrosis producing the characteristic calcification pattern visible on mammography, solid or comedo architectural pattern) with nuclear grade determining not only the radiographic calcification morphology (fine linear branching calcifications in high-grade comedo DCIS versus punctate or amorphous calcifications in low-grade DCIS) but also the biologic potential for invasive progression and the 10-year local recurrence risk after treatment, characterized by a highly variable natural history ranging from low-grade DCIS that progresses to invasive cancer in only 20–30% of untreated women over two decades (a biological indolence that has fueled active surveillance trials for low-risk DCIS, including the LORIS, LORD, and COMET trials) to high-grade DCIS with comedo necrosis that progresses to invasive cancer in 60–75% of untreated women within 10 years (a biologic trajectory more analogous to a locally advanced invasive cancer progenitor), hormone receptor-positive in approximately 70–80% of cases (ER-positive DCIS representing a hormone-responsive disease amenable to adjuvant endocrine therapy with tamoxifen or aromatase inhibitors that reduce ipsilateral recurrence and contralateral breast cancer risk), HER2-amplified in 40–60% of high-grade DCIS (a substantially higher HER2 amplification rate than invasive breast cancer, reflecting the particular propensity of HER2-driven clones to undergo high-grade in situ expansion before invasive progression), and treated primarily with breast conservation surgery (lumpectomy) plus adjuvant radiation therapy (whole breast irradiation or accelerated partial breast irradiation reducing ipsilateral recurrence from approximately 25–30% to 10–15% at 10 years after lumpectomy alone) or mastectomy (indicated for multicentric disease, inability to achieve negative margins after re-excision, patient preference, or BRCA germline mutation carriers), with the landmark NSABP B-17 and B-24 trials establishing radiation and tamoxifen as the standards of care for hormone receptor-positive DCIS after breast conservation, and with the ongoing clinical uncertainty about active surveillance for low-risk DCIS representing the most consequential unanswered question in breast oncology.
Ductal carcinoma in situ technology platforms — whether supporting mammography and digital breast tomosynthesis detection and biopsy coordination platforms (managing the detection, biopsy scheduling, biopsy result routing, and multidisciplinary tumor board presentation pipeline from screening mammography to confirmed DCIS diagnosis that spans 2–6 weeks and involves digital mammography workstations, tomosynthesis interpretation platforms, stereotactic and ultrasound biopsy scheduling systems, core needle biopsy pathology result routing platforms, and multidisciplinary conference scheduling infrastructure), nuclear grade and biomarker result routing platforms (routing ER, PR, HER2, and Ki-67 IHC results from the DCIS biopsy core to the breast oncology team, coordinating DCIS nuclear grade assessment and Van Nuys Prognostic Index scoring, and integrating genomic assay results from the Oncotype DX DCIS Score when ordered to risk-stratify radiation therapy benefit), surgical planning and margin management dashboards (tracking lumpectomy margin assessment, re-excision scheduling for close or positive margins, reconstruction consultation coordination, and mastectomy decision documentation for multicentric or margin-unachievable DCIS), adjuvant endocrine therapy initiation and adherence platforms (coordinating tamoxifen or aromatase inhibitor prescription, side effect monitoring, and 5-year adherence tracking for hormone receptor-positive DCIS), active surveillance clinical trial enrollment platforms (for institutions participating in COMET, LORIS, or LORD active surveillance versus surgery trials, coordinating enrollment, imaging surveillance schedule, and biopsy on progression protocols), and post-treatment surveillance scheduling platforms (coordinating annual mammography surveillance for local recurrence and contralateral primary cancer detection across the decade-plus follow-up arc that DCIS's long natural history demands) — must maintain the availability and performance standards that ductal carcinoma in situ's diagnostic pipeline complexity, nuclear grade-dependent treatment stratification, surgical margin management obligations, hormone receptor-guided endocrine therapy coordination, and long-term surveillance demands require. This guide explains why DCIS tech platforms need dedicated monitoring, what components to monitor, and how to build a monitoring strategy that matches the screening detection pipeline, biopsy coordination, biomarker routing, surgical margin management, endocrine therapy, and surveillance demands of modern ductal carcinoma in situ care.
Why DCIS Tech Platforms Require Specialized Monitoring Attention
Ductal carcinoma in situ management is defined by the complexity of the screening detection-to-treatment pipeline (where a finding on annual mammography must navigate biopsy scheduling, core needle biopsy pathology, IHC biomarker panel routing, multidisciplinary tumor board presentation, and surgical consultation within a 4–8 week window before patient anxiety, insurance authorization timelines, and surgeon availability pressures create clinical fragmentation), the nuclear grade and biomarker-dependent treatment stratification that determines whether adjuvant radiation and endocrine therapy are indicated (where high-grade DCIS with comedo necrosis generates a very different treatment recommendation from low-grade ER-positive DCIS where radiation benefit and active surveillance eligibility remain under active investigation), the surgical margin management imperative rooted in DCIS's mammographic extent frequently underestimating histopathologic extent (where the radiographic lesion measured on mammography or MRI often extends further in histopathologic sections than the imaging estimate predicts, generating high re-excision rates after breast conservation and demanding meticulous margin assessment infrastructure), and the long-term surveillance obligation extending 10–20 years for a disease where local recurrence and contralateral primary cancers accumulate over decades of follow-up in a primarily screen-detected patient population who are often asymptomatic and require active platform-driven surveillance reminder infrastructure. Technology failures in these domains create disruptions calibrated to the detection pipeline coordination timelines, biomarker routing precision, margin management urgency, endocrine therapy adherence, and decade-long surveillance obligations of ductal carcinoma in situ.
Mammography detection-to-biopsy coordination platforms drive the entire DCIS management pipeline. Mammography to biopsy coordination for ductal carcinoma in situ — where a screen-detected suspicious microcalcification on digital mammography or tomosynthesis requires diagnostic mammography workup (magnification views, additional compression views) within 1–2 weeks of the screening examination to characterize the morphology and distribution of calcifications (amorphous, coarse heterogeneous, fine pleomorphic, or fine linear branching — the BI-RADS calcification descriptors with increasing positive predictive value for malignancy), where a BI-RADS 4 or 5 assessment triggers a stereotactic core needle biopsy recommendation within 2–4 weeks of the diagnostic workup, where stereotactic biopsy scheduling (requiring the patient to remain prone on the dedicated stereotactic biopsy table, with specimen radiography confirming calcification retrieval in the biopsy cores), biopsy core pathology submission, and pathology result turnaround (3–5 business days for standard processing) must be coordinated through integrated scheduling and result routing infrastructure, where concordance assessment (evaluating whether the pathologic result — benign fibrocystic change, atypical ductal hyperplasia, DCIS, invasive carcinoma — is concordant with the imaging morphology and BI-RADS assessment that prompted biopsy) requires radiologist-pathologist communication managed through the biopsy coordination platform, where discordant benign pathology (benign result from a BI-RADS 4C or 5 calcification morphology) requires surgical excision biopsy escalation, and where the confirmed DCIS result must trigger multidisciplinary tumor board scheduling, breast MRI consideration, and surgical consultation within the clinical urgency window that patient anxiety and disease progression risk together define — requires platforms managing mammography workstation result flagging, diagnostic workup scheduling, stereotactic biopsy scheduling, specimen radiography result routing, pathology result delivery, radiologist-pathologist concordance communication, and multidisciplinary tumor board scheduling. Monitor mammography detection-to-biopsy platforms at 1-minute intervals during business hours. Alert immediately — pipeline coordination platform failures fragment the detection-to-diagnosis workflow, extending the biopsy confirmation timeline for patients experiencing the anxiety of a suspicious screening finding.
Nuclear grade and biomarker result routing determines radiation and endocrine therapy decisions. Biomarker routing for ductal carcinoma in situ — where ER and PR IHC results from the core needle biopsy (or surgical specimen) determine eligibility for adjuvant tamoxifen (premenopausal hormone receptor-positive DCIS) or aromatase inhibitor therapy (postmenopausal hormone receptor-positive DCIS) that reduces ipsilateral recurrence by approximately 30–50% relative to placebo in the NSABP B-24 and IBIS-II DCIS trials, where HER2 IHC and FISH results identify the 40–60% of high-grade DCIS that overexpress HER2 (informing experimental neoadjuvant HER2-targeted trial eligibility, though no standard adjuvant HER2-targeted therapy exists for DCIS outside trials), where Ki-67 IHC and nuclear grade assessment provide prognostic data for treatment stratification discussions, where the Oncotype DX DCIS Score (12-gene expression assay performed on formalin-fixed paraffin-embedded biopsy tissue, generating a score from 0 to 100 predicting 10-year local recurrence risk after lumpectomy alone) informs the radiation therapy benefit discussion for patients with ER-positive, surgically excised DCIS without clear high-grade features mandating radiation, where the DCIS Score result routing from Genomic Health (now Exact Sciences) laboratory to the breast oncologist typically spans 10–14 business days from specimen submission, and where biomarker result routing failures leave the multidisciplinary team unable to complete the treatment stratification discussion that determines whether the patient receives radiation therapy and endocrine therapy at the surgery planning conference — requires platforms managing ER/PR/HER2/Ki-67 IHC result routing, Oncotype DX DCIS Score specimen submission tracking, result turnaround monitoring, and score delivery to the multidisciplinary tumor board. Monitor biomarker routing platforms at 1-minute intervals during business hours. Alert immediately — biomarker platform failures delay the radiation and endocrine therapy stratification decisions that require ER status, nuclear grade, and DCIS Score confirmation before surgical planning can be finalized.
Surgical margin assessment platforms prevent the re-excision cascade that defines DCIS surgical management. Surgical margin management for ductal carcinoma in situ — where the standard negative margin for DCIS after breast conservation surgery is 2 mm (established by the SSO/ASTRO/ASCO guideline consensus for DCIS, a wider margin than the "no tumor at ink" standard for invasive cancer, reflecting DCIS's propensity for microscopic extension beyond the gross tumor margin) but where the margin distance criterion remains debated and institution-specific, where DCIS mammographic extent commonly underestimates pathologic extent (histopathologic extent exceeding mammographic extent in 20–50% of cases, generating the "surprise close margin" after lumpectomy sized to the mammographic lesion boundary), where intraoperative margin assessment methods including cavity shave margins (reducing re-excision rates by providing circumferential rim of tissue from the lumpectomy cavity walls for pathologic assessment) and intraoperative specimen radiography (confirming that the lumpectomy specimen contains the target calcifications in radiologic proximity to the specimen margin) require coordination through integrated radiology-pathology-surgical platforms, where the re-excision rate after initial DCIS lumpectomy ranges from 20–50% depending on lesion size, nuclear grade, and institutional margin protocol (among the highest re-excision rates of any breast surgery indication), and where re-excision scheduling within the 6–12 week post-lumpectomy window (before radiation planning commences) must be coordinated through surgical scheduling platforms that integrate margin status, re-excision indication, and operating room availability — requires platforms managing intraoperative specimen radiography result routing, cavity shave margin pathology routing, final margin report delivery, re-excision scheduling, and pre-radiation margin clearance confirmation. Monitor surgical margin platforms at 1-minute intervals during clinical operation. Alert immediately — margin platform failures delay the re-excision scheduling coordination that determines whether a patient achieves the negative margin required before radiation therapy planning.
Endocrine therapy initiation and adherence platforms sustain the 5-year risk reduction benefit. Adjuvant endocrine therapy coordination for ductal carcinoma in situ — where tamoxifen (20 mg daily for 5 years for premenopausal and postmenopausal hormone receptor-positive DCIS) or an aromatase inhibitor (anastrozole 1 mg daily or exemestane 25 mg daily for 5 years for postmenopausal hormone receptor-positive DCIS) reduces the risk of ipsilateral breast cancer events (DCIS recurrence or invasive recurrence in the treated breast) by approximately 30–50% and contralateral breast cancer by approximately 30–40% in the NSABP B-24, IBIS-II DCIS, and NSABP B-35 trials, where endocrine therapy adherence at 5 years is only 50–70% in population-based series (driven by side effects including hot flashes, arthralgias, sexual dysfunction, and vaginal dryness for tamoxifen, and menopausal symptoms plus bone density loss for aromatase inhibitors), where adherence monitoring platforms (pharmacy refill tracking, patient-reported side effect documentation, oncology follow-up visit adherence discussions) are associated with improved adherence rates in some programmatic interventions, and where the 5-year endocrine therapy completion documentation must be maintained for clinical outcome tracking and contralateral risk reduction documentation — requires platforms managing adjuvant endocrine therapy prescription initiation, pharmacy refill tracking integration, side effect documentation, adherence assessment at follow-up visits, and 5-year completion documentation. Monitor endocrine therapy platforms at 2-minute intervals during business hours. Alert at sustained outage — endocrine therapy coordination failures create gaps in the adherence support infrastructure that sustain the contralateral risk reduction benefit of 5-year endocrine therapy.
Active surveillance trial enrollment platforms enable the most consequential DCIS research of the decade. Active surveillance enrollment for ductal carcinoma in situ — where the COMET trial (Comparison of Operative to Monitoring and Endocrine Therapy, randomizing patients with grade 1 or 2 hormone receptor-positive DCIS to active surveillance versus standard surgery), LORIS trial (United Kingdom trial of active surveillance for low-risk DCIS), and LORD trial (European trial of active surveillance for low-risk DCIS) are actively enrolling patients at participating institutions, where enrollment eligibility assessment (confirming low-risk DCIS by nuclear grade, hormone receptor status, and size criteria), patient counseling (explaining the 50% randomization to active surveillance including surveillance mammography every 6–12 months and biopsy on radiographic progression), informed consent documentation, randomization, and surveillance schedule enrollment require coordinated platforms at trial-participating institutions, and where platform failures during the informed consent or randomization window delay enrollment and may generate attribution inconsistencies in trial data — requires platforms managing active surveillance eligibility screening, patient counseling documentation, informed consent tracking, randomization execution, surveillance imaging schedule enrollment, and biopsy-on-progression result routing. Monitor active surveillance trial platforms at 2-minute intervals during business hours. Alert at sustained outage — trial enrollment platform failures delay patient randomization at institutions participating in the most important DCIS clinical trials of the current era.
What to Monitor on a DCIS Tech Platform
Mammography Detection-to-Biopsy Coordination
Monitor digital mammography and tomosynthesis workstation result flagging (BI-RADS 0, 4, and 5 result routing to diagnostic radiology), diagnostic magnification and compression view scheduling (target 1–2 weeks from screening finding), stereotactic core needle biopsy scheduling (target 2–4 weeks from diagnostic workup), specimen radiography result routing during biopsy (confirming calcification retrieval in cores), core needle biopsy pathology result routing (ER, PR, HER2 IHC, nuclear grade), radiologist-pathologist concordance assessment communication, discordant-benign escalation routing (surgical excision biopsy scheduling for discordant results), multidisciplinary tumor board scheduling trigger, and breast MRI consultation routing (for patients with dense breast tissue, positive family history, or lobular features on core biopsy) at 1-minute intervals during business hours. Alert immediately — detection pipeline platform failures fragment the biopsy coordination workflow, extending the diagnosis confirmation timeline for screen-detected DCIS patients experiencing biopsy anxiety.
Nuclear Grade and Biomarker Result Routing
Monitor ER, PR, and HER2 IHC result routing from pathology to breast oncology team (target 3–5 business days from surgical biopsy specimen), HER2 FISH result routing for IHC 2+ equivocal cases, Ki-67 IHC result routing, nuclear grade assessment and Van Nuys Prognostic Index scoring documentation, Oncotype DX DCIS Score specimen submission tracking (confirming formalin-fixed paraffin-embedded block submission to Genomic Health/Exact Sciences), DCIS Score result turnaround tracking (target 10–14 business days), DCIS Score delivery to multidisciplinary tumor board (for radiation therapy stratification discussion), and biomarker integration with surgical planning conference scheduling at 1-minute intervals during business hours. Alert immediately — biomarker routing failures delay the treatment stratification decision that determines whether radiation and endocrine therapy are recommended.
Surgical Margin Assessment and Re-Excision Scheduling
Monitor intraoperative specimen radiography result routing (confirming calcification-to-margin proximity during lumpectomy), cavity shave margin pathology routing (specimen radiograph interpretation and shave margin histologic result delivery to surgical and radiation oncology teams), final lumpectomy specimen margin report delivery (margin distance in millimeters, DCIS grade at margin, necrosis at margin), re-excision scheduling for close (<2 mm) or positive margins (target scheduling within 6–8 weeks of initial lumpectomy), mastectomy decision documentation for patients with DCIS extent exceeding lumpectomy re-excision candidacy, radiation oncology pre-planning margin clearance confirmation, multidisciplinary margin discussion documentation, and DCIS extent discordance documentation (cases where histopathologic extent exceeds mammographic estimate at time of lumpectomy planning) at 1-minute intervals during clinical operation. Alert immediately — margin routing failures delay the re-excision scheduling and radiation planning coordination for a disease with among the highest re-excision rates in breast surgery.
Adjuvant Radiation Therapy Coordination
Monitor radiation oncology consultation scheduling (following confirmed negative margins), whole breast radiation therapy simulation and planning scheduling, accelerated partial breast irradiation candidacy assessment (for patients meeting ASTRO suitable-patient criteria: ≥50 years, unicentric DCIS ≤3 cm, negative surgical margins ≥3 mm), radiation planning approval and treatment start scheduling, hypofractionated whole breast radiation scheduling (26 Gy in 5 fractions, or 40 Gy in 15 fractions), boost dose documentation (tumor bed boost for high-grade DCIS or close margins), radiation treatment completion documentation, and radiation-related toxicity routing at 2-minute intervals during active treatment. Alert at sustained outage — radiation coordination failures delay the adjuvant radiation initiation that reduces ipsilateral recurrence after breast conservation for DCIS.
Adjuvant Endocrine Therapy Initiation and Adherence
Monitor ER-positive DCIS endocrine therapy prescription routing (tamoxifen vs. aromatase inhibitor decision documentation including menopausal status confirmation, bone density baseline for aromatase inhibitor-eligible patients), pharmacy prescription confirmation receipt, 3-month follow-up visit scheduling (side effect assessment and dose adjustment), 6-month and annual refill adherence tracking, endocrine therapy side effect documentation (hot flashes, arthralgias, vaginal dryness, bone density loss), bone density monitoring scheduling for aromatase inhibitor-treated patients (baseline DXA, 1–2 year interval monitoring), and 5-year endocrine therapy completion documentation at 2-minute intervals during business hours. Alert at sustained outage — endocrine therapy platform failures create adherence monitoring gaps that reduce the 5-year contralateral risk reduction benefit in hormone receptor-positive DCIS.
Long-Term Surveillance Scheduling and Local Recurrence Detection
Monitor post-treatment annual mammography scheduling (ipsilateral and contralateral breast, beginning 6 months post-radiation to establish a post-treatment baseline), digital breast tomosynthesis surveillance scheduling for patients with prior calcification-detected DCIS (to maximize calcification recurrence detection sensitivity), imaging result routing with comparison to prior surveillance mammography, interval biopsy scheduling for suspicious new calcifications or masses on surveillance mammography, invasive recurrence detection and re-staging workup routing, new contralateral primary breast cancer detection routing, and surveillance scheduling continuity across the 10–20 year follow-up arc appropriate for DCIS's long natural history at 2-minute intervals during business hours. Alert at sustained outage — surveillance platform failures allow annual imaging lapses that delay detection of ipsilateral recurrence (whether DCIS recurrence or invasive recurrence) and contralateral primary cancers in a large patient population whose decade-long surveillance obligation demands robust scheduling infrastructure reliability.
Authentication and Multidisciplinary Team Access
Monitor authentication at 1-minute intervals, 24/7. DCIS programs coordinate across screening radiology (mammography and tomosynthesis), diagnostic radiology (biopsy guidance and specimen radiography), surgical pathology (core biopsy and margin assessment), breast surgery (lumpectomy and re-excision), radiation oncology (whole breast and APBI planning), medical oncology (endocrine therapy and biomarker stratification), genetics (BRCA testing for selected patients), and survivorship — authentication failures simultaneously block the multidisciplinary team whose biomarker-guided treatment stratification discussions depend on authentication-gated result routing platforms.
SSL Certificates
Monitor SSL certificate expiry across all patient portals, mammography result delivery platforms, biopsy coordination systems, pathology result routing platforms, radiation therapy planning dashboards, endocrine therapy adherence platforms, active surveillance trial enrollment systems, and long-term surveillance scheduling platforms. Certificate errors disrupt the detection pipeline and biomarker routing infrastructure that ductal carcinoma in situ's mammography-to-treatment coordination demands.
HIPAA and Oncology Data Privacy Considerations
Ductal carcinoma in situ technology platforms handle sensitive PHI including mammography and tomosynthesis screening and diagnostic imaging studies, core needle biopsy pathology reports with ER/PR/HER2 biomarker results, Oncotype DX DCIS Score genomic assay results (commercial molecular diagnostic PHI), surgical margin pathology reports, radiation therapy planning records, adjuvant endocrine therapy prescription and adherence records, germline genetic testing results (BRCA1/2 and multi-gene panel for selected patients), active surveillance clinical trial enrollment records, and long-term surveillance imaging spanning 10–20 years of follow-up. HIPAA Security Rule requirements for PHI availability and integrity apply across all platform components.
For platforms managing Oncotype DX DCIS Score genomic results — where commercial genomic diagnostic data informs treatment decisions with potential insurance implications — privacy protections must reflect the genomic sensitivity of molecular diagnostic results and the GINA protections applicable to genomic health information. The large DCIS patient population (55,000–60,000 new diagnoses annually) creates substantial aggregate PHI volume across mammography, pathology, genomics, radiation, endocrine therapy, and surveillance domains. Availability monitoring provides operational documentation relevant to HIPAA Security Rule administrative safeguard compliance for breast cancer programs managing DCIS's intersection of screening, diagnostic, genomic, treatment, and decades-long surveillance PHI.
Alerting Strategy for DCIS Tech Platforms
Immediate alerting for biopsy result routing: Biopsy coordination platforms during active result delivery windows, where delayed DCIS confirmation extends the patient anxiety period and delays surgical planning consultation.
Immediate business-hours alert: Nuclear grade and biomarker result routing platforms during treatment stratification discussions, surgical margin assessment platforms during clinical operation, and mammography detection pipeline platforms during screening result processing.
Sustained-failure alert (10–15 minutes): Adjuvant radiation coordination platforms, endocrine therapy adherence platforms, active surveillance trial enrollment systems, and long-term surveillance scheduling platforms.
30-day advance warning: SSL certificates across all domains.
Vigilmon's multi-region monitoring confirms DCIS platform availability from the geographies where high-volume breast cancer centers with dedicated mammography screening programs, multidisciplinary tumor boards, stereotactic biopsy suites, genomic assay partnerships, and long-term survivorship programs concentrate — important for a disease whose scale (55,000–60,000 new diagnoses annually), screening detection pipeline complexity, biomarker-guided treatment stratification, and decade-long surveillance infrastructure demands make platform reliability a population-level clinical quality imperative.
Status Page for DCIS Care Team Communication
A real-time status page gives radiologists managing mammography screening and biopsy guidance, breast surgeons planning lumpectomy and managing margins, radiation oncologists planning whole breast radiation and APBI, medical oncologists managing biomarker stratification and endocrine therapy, surgical pathologists routing nuclear grade and margin assessments, molecular pathology services routing Oncotype DX DCIS Scores, and survivorship coordinators managing decade-long surveillance schedules immediate platform visibility. During a biomarker result routing platform outage when the multidisciplinary tumor board has convened to discuss a 58-year-old woman with biopsy-confirmed DCIS where the ER result is pending from the molecular pathology laboratory — where the radiation oncologist and medical oncologist need the ER status to determine whether adjuvant endocrine therapy discussion is indicated at today's surgical planning conference — a status page enables immediate contingency protocol activation so that the pathologist can communicate the ER result by telephone and the tumor board can complete the treatment stratification discussion while the result routing platform is restored.
Include the status page URL in biopsy result delivery downtime procedures, surgical margin emergency communication workflows, endocrine therapy prescription system downtime procedures, and surveillance scheduling fallback protocols.
Vigilmon Setup for DCIS Tech Platforms
A practical starting configuration:
| Monitor | Check Interval | Alert Channel | |---------|----------------|---------------| | Authentication | 1 min | Slack + PagerDuty (24/7) | | Mammography / tomosynthesis detection pipeline | 1 min | Slack + PagerDuty (business hours) | | Stereotactic biopsy scheduling and result routing | 1 min | Slack + PagerDuty (business hours) | | ER / PR / HER2 / Ki-67 IHC result routing | 1 min | Slack + PagerDuty (business hours) | | Oncotype DX DCIS Score routing | 1 min | Slack + PagerDuty (business hours) | | Intraoperative specimen radiography routing | 1 min | Slack + PagerDuty (business hours) | | Surgical margin report delivery | 1 min | Slack + PagerDuty (business hours) | | Re-excision scheduling workflow | 1 min | Slack + PagerDuty (business hours) | | Radiation therapy coordination platform | 2 min | Slack (business hours) | | Endocrine therapy prescription and adherence | 2 min | Slack (business hours) | | Active surveillance trial enrollment | 2 min | Slack (business hours) | | Annual mammography surveillance scheduling | 2 min | Slack (business hours) | | Patient communication portal | 2 min | Slack (business + evening hours) | | SSL: all domains | Daily | Email (30-day warning) |
Getting started:
- Create a free account at vigilmon.online
- Add authentication endpoints at 1-minute intervals with 24/7 alerting
- Configure mammography detection pipeline and tomosynthesis result flagging with immediate business-hours alerting
- Add stereotactic biopsy scheduling and pathology result routing with immediate alerting
- Configure ER/PR/HER2/Ki-67 IHC result routing with immediate alerting
- Add Oncotype DX DCIS Score submission tracking and result routing with immediate alerting
- Configure intraoperative specimen radiography and cavity shave margin result routing with immediate alerting
- Add surgical margin report delivery and re-excision scheduling with immediate alerting
- Configure adjuvant radiation therapy coordination with sustained-failure alerting
- Add endocrine therapy prescription and adherence monitoring with sustained-failure alerting
- Configure active surveillance trial enrollment platforms with sustained-failure alerting
- Add annual surveillance mammography scheduling with sustained-failure alerting across the 10–20 year follow-up horizon
- Enable SSL certificate monitoring across all screening, diagnostic, pathology, treatment, and survivorship domains
- Add the status page URL to biopsy result delivery downtime procedures, margin assessment fallback protocols, and surveillance scheduling emergency workflows
Conclusion
Ductal carcinoma in situ technology platforms are embedded in clinical decisions where mammography detection-to-biopsy coordination platform availability during the period when a 54-year-old woman presenting for routine annual screening mammography has a 1.2 cm cluster of fine linear branching calcifications detected on tomosynthesis acquisition and flagged as BI-RADS 4C — where the diagnostic workup scheduling platform must route the BI-RADS 4C finding to the diagnostic radiology scheduling queue for magnification view workup within 5 business days, where the stereotactic biopsy scheduling platform must generate a biopsy appointment within 10 business days of the diagnostic workup confirming fine pleomorphic calcifications requiring tissue sampling, where the core biopsy pathology platform must route the ER-positive high-grade DCIS result to the breast oncology tumor board scheduling system to trigger the multidisciplinary conference, and where a 48-hour biopsy scheduling platform outage in the period between the diagnostic workup and biopsy scheduling extends her diagnosis confirmation by one week and the patient experiences an additional week of uncertainty from a BI-RADS 4C finding that carries a 60–70% positive predictive value for malignancy — cannot be disrupted by platform failures in the detection-to-diagnosis pipeline; where surgical margin assessment platform availability during the period when a 61-year-old woman has undergone lumpectomy for 2.3 cm intermediate-grade ER-positive DCIS and the surgical pathologist has identified a 1 mm close margin at the anterior aspect of the specimen — where the margin platform must route the margin status to the breast surgeon's dashboard within 3 business days of surgery, where the surgeon requires the margin distance to trigger re-excision scheduling within the 8-week post-lumpectomy window, and where a 96-hour margin routing outage delays the re-excision scheduling decision past the point where the patient has already begun radiation planning consultations, requiring a complex re-sequencing of the re-excision and radiation planning timeline — cannot be disrupted by margin dashboard failures at the re-excision scheduling decision point; and where Oncotype DX DCIS Score result routing platform availability during the period when a 63-year-old woman with low-nuclear-grade ER-positive DCIS has been counseled that her DCIS Score result will determine the radiation therapy recommendation — where the multidisciplinary tumor board has deferred the radiation therapy decision pending the DCIS Score, where the score has returned at 27 (low risk, 10-year recurrence risk 12% after lumpectomy alone) from Genomic Health, where the radiation oncologist is planning to use the low-risk DCIS Score to support an active surveillance conversation rather than standard radiation, and where the result routing platform outage leaves the oncologist unable to access the DCIS Score result on the day of the radiation consultation, requiring rescheduling of a shared decision-making conversation the patient has emotionally prepared for — cannot be disrupted by genomic result routing failures at the treatment stratification discussion window. A biopsy scheduling platform that fails when patients are experiencing BI-RADS 4C biopsy anxiety, a margin dashboard that delays re-excision scheduling past the pre-radiation window, an Oncotype DCIS Score routing platform that fails on the day of the radiation stratification conversation — these are not IT incidents. They are clinical disruptions in the management of the most common breast cancer diagnosis in the United States, affecting a patient population whose mammography-detected noninvasive cancer is highly curable when detection pipeline integrity, biomarker routing precision, surgical margin management rigor, and decade-long surveillance infrastructure reliability are maintained.
Uptime monitoring gives ductal carcinoma in situ tech teams the detection capability to identify failures within seconds, trigger immediate clinical downtime procedures, and demonstrate to breast oncology programs, screening radiology services, molecular pathology laboratories, multidisciplinary tumor boards, and compliance auditors that platform operational reliability matches the mammography detection pipeline coordination complexity, nuclear grade and biomarker routing urgency, surgical margin management precision, endocrine therapy adherence support, active surveillance trial coordination, and decade-long surveillance duration demands of modern ductal carcinoma in situ care.
Start monitoring your DCIS care tech platform for free at vigilmon.online — HTTP/HTTPS monitoring, multi-region consensus alerting, SSL certificate monitoring, automatic status page, Slack and webhook alerts. No agent required. No credit card.
Tags: #monitoring #DCIS #ductalcarcinomainsitu #breastcancer #mammography #tomosynthesis #stereotacticbiopsy #OncotypeDX #DCISScore #surgicalmargins #reexcision #radiationtherapy #endocrinetherapy #tamoxifen #aromataseInhibitors #activesurveillance #COMET #LORIS #cancertech #healthtech #digitalhealth #uptime #sre #HIPAA